Immune-Bridging drugs could open kidney transplants to more donors

NCT ID NCT07706205

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-stage trial tests whether two immune-engaging drugs, blinatumomab and teclistamab, can safely lower blood-group antibodies in people awaiting a living-donor kidney transplant that is not blood-type compatible. The goal is to see if these drugs can prepare the body to accept a mismatched kidney. The study involves 20 adults with end-stage kidney disease and tracks antibody levels and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: two bispecific T-cell engager drugs called blinatumomab and teclistamab
What this could lead to: If successful, this approach could expand the donor pool for kidney transplants by making blood-type mismatches less of a barrier.
What could go wrong: This is a very early, small trial (20 people) focused on safety and antibody reduction, not long-term transplant success. The drugs can cause serious side effects like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABO BLOOD TYPE INCOMPATIBLE KIDNEY TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABO BLOOD TYPE INCOMPATIBLE KIDNEY TRANSPLANTATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.